Ruxolitinib
Potent and selective JAK1&2 inhibitor, IC50s=2.7, 4.5 and 322 nM for JAK1, JAK2 and JAK3 respectively. Blocks IL-6 signaling (IC50=281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50=127 nM). Inhibits the proinflammatory secretome of senescent cells. The JAK1 S646P mutant is highly sensitive to ruxolitinib. Clinically useful anticancer agent.
$133.00 – $285.00
-
Product Details
- Physical State: White powder
- Temperature Storage: -20°C
- Temperature Shipping: Ambient
- Molecular Mass: 306.4
-
References
1. Verstovsek, S., et al., (2009) Hematol. Am. Soc. Hematol. Educ. Program, (1)636
2. Quintas-Cardama, A., et al., (2010) Blood, 115 : 3109
3. Farr, J.N., et al., (2017) Nat. Med., 23 : 1072
4. Li, Q., et al., (2017) Oncotarget, 8 : 34687
